The role of FDG-PET/CT in gynaecological cancers
| Autor: | E. K. Moore, Susan Cross, Andrea Rockall, Sean Flanagan, Norbert Avril |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
PET/CT diagnosis Genital Neoplasms Female medicine.medical_treatment Review Disease Multimodal Imaging cervix cancer Fluorodeoxyglucose F18 Humans Medicine Radiology Nuclear Medicine and imaging vulval cancer FDG-PET Fluorodeoxyglucose PET-CT Radiological and Ultrasound Technology medicine.diagnostic_test business.industry Endometrial cancer staging General Medicine medicine.disease FDG-PET/CT Radiation therapy treatment monitoring PET ovarian cancer Oncology Positron emission tomography gynaecological cancers Positron-Emission Tomography endometrial cancer Female Tomography Radiology Radiopharmaceuticals Molecular imaging Tomography X-Ray Computed business medicine.drug |
| Zdroj: | Cancer Imaging |
| ISSN: | 1470-7330 |
| Popis: | There is now a growing body of evidence supporting the use of fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in gynaecological malignancies. Although this molecular imaging technique is becoming increasingly available, PET/CT remains an expensive imaging tool. It is essential to be familiar with the circumstances in which FDG-PET/CT can add value and contribute to patient management and indeed to know when it is unlikely to be of benefit. It is also important to understand and recognize the potential pitfalls. FDG-PET/CT has been most widely adopted for staging patients with suspected advanced disease or in suspected recurrence, offering a whole-body imaging approach. However, there is great potential for this technique to act as a predictive biomarker of response to treatment, as well as a prognostic biomarker. In addition, FDG-PET images may now be incorporated into radiotherapy planning in order to refine the delineation of dose according to metabolically active sites of disease. This article reviews the literature that provides the evidence for the use of FDG-PET in gynaecological malignancies, identifies areas of real benefit and future potential, and highlights circumstances where there is limited value. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink